Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1

Conclusions: In PATENT-1, riociguat significantly improved pulmonary artery stiffness in pts with PAH. Improvements in PAC correlated with improvements in pulmonary hemodynamics. n¹Riociguat 2.5 mg–maxPlaceboLS mean difference from baseline to Week 12 (95% CI)p-valueBaselineWeek 12BaselineWeek 12PAC, mL/mmHg227/1081.5±0.81.9±1.21.4±1.01.4±0.9+0.44 (0.26 to 0.62)<0.0001SAC, mL/mmHg223/1071.2±0.51.6±0.61.2±0.61.4±0.7+0.18 (0.07 to 0.30)0.0013Data are mean±SD unless otherwise indicated; ¹riociguat 2.5 mg–max/placebo.

Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Preston, I., Al-Naamani, N., Ghio, S., Ghofrani, H.-A., Hassoun, P., Nikkho, S., Fritsch, A., Torbicki, A. Tags: 4.3 Pulmonary Circulation and Pulmonary Vascular Disease Source Type: research